throbber
Management of Urinary Incontinence
`
`George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD
`
`DISEASE OVERVIEW
`Urinary incontinence (UI) may be defined as any involuntary or
`abnormal urine loss. UI is characterized by lower urinary tract
`symptoms (LUTS), which include both storage and voiding prob-
`lems. UI can be further defined by the patient’s presentations and
`symptoms. Urge urinary incontinence (UUI) is defined as invol-
`untary urine leakage associated with urgency. Stress urinary in-
`continence (SUI) is defined as involuntary urine leakage associated
`with specific activities (e.g., sneezing and coughing. Mixed urinary
`incontinence (MUI) includes features of both UUI and SUI.1–3
`Overflow incontinence (OFI) is caused by a hypotonic bladder,
`bladder outlet obstruction, or other forms of urinary retention. OFI
`may result in LUTS and in the loss of small amounts of urine; it most
`often occurs in men with benign prostatic hyperplasia (BPH).4
`The term overactive bladder (OAB) is often used to describe UI.
`OAB comprises a constellation of symptoms typically charac -
`terized by urgency, with or without UUI, accompanied by fre-
` quency and nocturia.1
`
`Epidemiology
`Approximately 10 million patients in the U.S. have UI, which is
`associated with significant morbidity and decreased quality of life.
`In 2007, it was estimated that more than 25 million people in the
`U.S. experienced episodes of UI. The prevalence of UI is higher
`in women than in men 80 years of age or younger, but both men
`and women are affected almost equally after age 80. UI may be
` associated with certain comorbidities, including hypertension
`and depression, although these associations are not fully under-
`stood.5,6 Among women, the incidence of UI is highest in
` Caucasians (7.3/100 person-years), followed by Asians (5.7/100
` person-years) and African-Americans (4.8/100 person-years).7
`As a result of the social stigma associated with UI or the as-
`sumption that UI is a normal part of aging, the prevalence of this
`disorder may be underestimated because of unreported cases.8 UI
`is also often undocumented upon hospital discharge; it is a
` neglected syndrome in nursing facilities; and it is underreported
`by health care professionals, who may view the condition as a
`symptom rather than as a medical problem.9,10
`UI is primarily associated with aging, affecting up to 30% of
` elderly people. It occurs in 85% of long-term-care patients and is
`often the reason for admission to these facilities.11,12 The prevalence
`of UI in nursing homes remains high, and the care of nursing-home
`residents with UI is the subject of clinical research.13,14 In addition,
`UI is one of the measures used by the Centers for Medicare and
`Medicaid Services (CMS) to assess quality of care.15–17
`Annual direct and indirect costs of managing UI in the U.S. is
`estimated at $25 billion for patients over 65 years of age.18,19 The
`direct costs of UI include diagnostic procedures and the various
`treatment options, including pharmacotherapy.20 Indirect costs
`include complications and disabilities, such as insomnia, falls,
`
`Dr. DeMaagd is Associate Dean of Academic Administration and Pro-
`fessor of Pharmacy at the Union University School of Pharmacy in
` Jackson, Tenn. Dr. Davenport is a Urologist at The Jackson Clinic in
` Jackson.
`
`Accepted for publication January 23, 2012.
`
` depression, caregiving, and nursing-home placement.10,21 The
` indirect costs of UI are associated with a significant decrease in
`health-related quality of life, especially in women. Other “costs” of
`UI are difficult to measure but are significant. These include the
`consequences of social withdrawal or isolation resulting from the
`perceived stigma of UI or from the fear of leakage or odor.22–24
`
`Bladder Anatomy and Physiology
`The anatomy and physiology of the bladder are complex, but a
`basic understanding of these topics is essential in order to appre-
`ciate the various types of UI and their management.25,26 Figure 1
`illustrates the basic anatomic structures and nervous system
`“wiring” involved in bladder function, including the detrusor mus-
`cle, the internal and external sphincters (bladder neck and prox-
`imal urethra, respectively), and their neurological components.
`Reduced activation of the sympathetic nervous system (SNS)
`results in relaxation of the detrusor muscle, closure of the sphinc-
`ter, and bladder filling. When the volume of urine in the bladder
`reaches 200 to 400 mL, the sensation of urge to void is relayed via
`the spinal cord to the brain centers. Voluntary voiding (micturition)
`involves the parasympathetic nervous system and the voluntary
`somatic nervous system. Influences from these systems cause
` contractions of the detrusor muscle and corresponding somatic
`nervous activity, leading to sphincter relaxation.26–31
`
`Etiology and Risk Factors
`Multiple factors, including age-related physiological changes,
`may result in or contribute to the various syndromes of UI. Both
`genitourinary and non-genitourinary factors may contribute to
`incontinence in aging patients. Age-related functional changes in
`the urinary tract (detrusor overactivity, impaired bladder con-
`tractility, decreased pressure in urethra closure, atrophy of ure-
`thral areas, and prostatic hypertrophy) may contribute to UI.32 In
`women, risk factors for these genitourinary changes include mul-
`tiple or complex vaginal deliveries, high infant birth weight, a his-
`tory of hysterectomy, and physiological changes related to the tran-
`sition to postmenopause. Smoking, a high body mass index, and
`constipation are also associated with an increased risk of UI.33–37
`Pathophysiological causes of UI include lesions in higher mic-
`turition centers, in the sacral spinal cord, and in other neurologi-
`cal areas as well. UI may also be associated with numerous
` comorbidities, such as Parkinson’s disease, Alzheimer’s disease,
`
`Key Abbreviations
`
`benign prostatic hyperplasia
`lower urinary tract symptoms
`mixed urinary incontinence
`overactive bladder
`overflow incontinence
`stress urinary incontinence
`urinary incontinence
`urinary tract infection
`urge urinary incontinence
`
`BPH
`LUTS
`MUI
`OAB
`OFI
`SUI
`UI
`UTI
`UUI
`
`Disclosure: The authors report that they have no financial, com-
`mercial, or industrial relationships in regard to this article.
`
`Vol. 37 No. 6 (cid:129) June 2012 (cid:129) P&T® 345
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1016 - Page 1
`
`

`
`Management of Urinary Incontinence
`
`cerebrovascular disease, diabetes, hypertension, obstructive sleep
`apnea, and normal-pressure hydrocephalus. Functional factors, in-
`cluding mobility and dexterity, along with reaction time and lack
`of access to a bathroom facility, may also contribute to UI.33–37
`Reversible causes of UI, often described by the mnemonic
` DIAPPERS, include urinary-tract infections (UTIs), stool impaction,
`and drugs (Table 1).35–44 Incontinence in older adults may or may
`not be associated with the genitourinary system. Pharmacological
`causes and contributors should be considered in patients with UI,
`especially if they are taking multiple medications (Table 2).32,38–44
`Primary care providers and specialists should work as a team to
`manage patients with UI and to evaluate the broad spectrum of fac-
`tors that may contribute to incontinence in older adults.32,38,40
`
`Diagnosis and Evaluation
`Patients with signs and symptoms of UI should undergo a com-
`plete medical evaluation to rule out reversible causes of the dis-
`order. Formulating an accurate diagnosis may require the partic-
`ipation of clinicians with specialized training in urology. Clinically,
`patients with UI present with a variety of symptoms, depending on
`the type and severity of the condition. Patients with UUI usually
`experience urgency episodes that result in loss of urine. Women
`with SUI usually experience small amounts of leakage related to
`external stimuli, such as coughing or sneezing. Men with OFI sec-
`
`ondary to BPH usually experience LUTS, including difficulty ini-
`tiating a urine stream, the presence of a weak stream, a sense of
`incomplete emptying, nocturia, and dribbling.1,4,25,38 The impor-
`tance of a correct diagnosis cannot be overemphasized. A complete
`review of the patient’s history, including comorbidities, is neces-
`sary for the development of an appropriate treatment plan.47,48
`Urodynamic studies assist clinicians in determining the precise
`cause of UI and are an important part of the diagnostic process.
`Urodynamic assessments include a variety of measures that
` evaluate urine flow, including flow rate, post-void residual urine,
`filling cystometry, bladder pressure, and urethral pressure. These
` assessments provide an extensive description of lower urinary
`tract function and are helpful in determining the appropriate man-
`agement strategy or in evaluating treatment failures.1,49–51
`Because UI in older adults is associated with a high risk of
` institutionalization and comorbidities, including depression and
`UTIs, appropriate assessment of transient UI is essential. Transient
`UI may have an abrupt onset and may last less than 6 months. Be-
`cause caregivers and health care professionals may erroneously
`consider UI an inevitable consequence of aging, failure to identify
`transient forms of the disorder may result in a permanent diag-
`nosis and poor patient outcomes. Various tools, including bladder
`diaries and the mnemonic described in Table 1, should be helpful
`in identifying and treating underlying causes of transient UI.
`
`Brain (micturition center)
`
`Sympathetic nervous system (SNS)
`(beta-adrenergic receptors)
`
`SNS
`inhibition
`
`Spinal cord
`(thoracic and
`lumbar regions)
`
`Detrusor muscle
`
`Bladder
`
`Parasympathetic
`nervous system (PNS)
`(cholinergic receptors)
`
`Internal
`sphincter
`(alpha-adrenergic
`receptors)
`
`External
`sphincter
`
`Somatic (pudendal) nerve
`
`Urethra
`
`(Sacral region)
`
`Figure 1 Bladder anatomy and physiology.
`
`Illustration by Alison Schroeer
`
`346 P&T® (cid:129) June 2012 (cid:129) Vol. 37 No. 6
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1016 - Page 2
`
`

`
`Management of Urinary Incontinence
`
`Initial questions for patients suspected of having UI may include
`“Have you ever leaked urine?” or “Have you lost bladder control?”
`Bladder diaries may be used to assess patterns of voiding, fre-
`quency, and volume. Questionnaires may also be helpful, although
`they depend on the patient’s or the caregiver’s memory.45–49
`Because only approximately 20% of women with UI seek med-
`ical attention, and because there is the misconception that urinary
`leakage is a normal part of aging, health care practitioners should
`aim discussions at identifying women who are experiencing UI and
`need further evaluation.7,41,51,52 Pharmacists should have a thor-
`ough understanding of UI and its pharmacotherapeutic manage-
`ment. A comprehensive understanding of UI is necessary to opti-
`mize pharmacotherapy and to allow the pharmacist to review the
`patient’s medical profile for medications that might be causing or
`exacerbating the disorder.33,34,25,42 Because many patients with UI
`are older, it is often necessary to make dosage adjustments in their
`medications. Because of changes in both pharmacokinetics and
`pharmacodynamics in elderly populations, additional monitoring
`to avoid drug-related adverse events is required.52
`
`Nonpharmacological Management:
`Conservative Measures and Exercises
`The management of UI should include an evaluation of poten-
`tial reversible contributors and trials of nonpharmacological inter -
`ventions, which depend on the type of UI identified. Clinical stud-
`ies support proper nutrition, the avoidance of constipation, weight
`loss, and physical activity as beneficial in improving symptoms.53–
`61 A study of weight loss in overweight women reported a clinically
`relevant reduction in the frequency of both stress and urge in-
`continence episodes.58 Women who are able to engage in regular
`daily exercise of moderate intensity are reported to have a lower
`incidence of UI than sedentary women, although the ability to ex-
`ercise may be limited by physical disabilities in elderly women.
`Other non-drug interventions for UI include prompted or timed
`voiding, habit retraining, and praises for appropriate toileting. Suc-
`cess with these interventions requires the patient’s awareness of
`the need to void and the ability to delay voiding if necessary. These
`interventions, along with exercise, are associated with modest
`
`Table 1 Reversible Causes of Urinary Incontinence
`(DIAPPERS)
`
`Delirium
`D
`Infection (urinary tract)
`I
`Atrophic
`A
`Pharmacological
`P
`Psychological
`P
`Endocrine/excess urine output
`E
`Restricted mobility
`R
`Stool impaction
`S
`Data adapted from references 38–46.
`
`and short-term improvements in daytime UI. Absorbent products
`or pads may also be helpful to some patients; the use of these prod-
`ucts should be based on the needs of the patient rather than on the
`convenience of the caregiver or facility staff. The drugs listed in
`Table 2 are often problematic in these patients and may contribute
`to or exacerbate UI; thus, evaluation may be necessary.62–68
`Pelvic floor (Kegel) muscle training and bladder training have
`been beneficial in resolving or improving UI.69,70 Kegel exercises
` involve strengthening and retraining the detrusor bladder muscle to
`regain some control of urinary function. Evidence supports the use
`of this behavioral intervention in the treatment of UUI, SUI, and MUI.
`Choi et al. suggested that these exercises might be most effective
`in younger women with predominantly stress-related incontinence.71
`The training process involved in learning these exercises may
`be complex for some patients, especially older adults with mem-
`ory disorders.69–71 Comparisons of various conservative tech-
`niques, using a device that monitors compliance and the per-
`formance of exercises, showed that pelvic floor exercises, alone
`or in combination with biofeedback or electrical stimulation, may
`be beneficial for patients with SUI or MUI.53,54,56,72
`The treatment of UI in older adults living in the community is
`
`Table 2 Medications That Can Cause or Exacerbate Urinary Incontinence
`
`Classification
`Alpha-adrenergic agonists
`
`Medication
`Nasal decongestants
`
`Alpha-adrenergic antagonists
`
`Prazosin, terazosin, doxazosin, silodosin, alfuzosin
`
`Activity
`Urinary retention in men with overflow
` incontinence related to BPH
`
`Urethral relaxation; may cause or exacerbate
`stress incontinence in women
`
`Anticholinergic drugs
`
`Antihistamines, tricyclic antidepressants, some
` antipsychotics
`
`Anticholinergic actions; urinary retention in
` overflow incontinence or impaction
`
`Antineoplastic drugs
`
`Vincristine
`
`Urinary retention
`
`Calcium-channel blockers
`
`Dihydropyridines (e.g., nifedipine)
`
`Urinary retention; nocturnal diuresis resulting
`from fluid retention
`
`Diuretics
`
`Narcotic analgesics
`
`Sedatives/hypnotics
`
`Furosemide, bumetanide
`
`Opiates
`
`Long-acting benzodiazepines (e.g., diazepam,
` flurazepam)
`
`Polyuria; frequency; urgency
`
`Urinary retention; sedation
`
`Sedation; delirium; immobility
`
`BPH = benign prostatic hyperplasia.
`Data adapted from references 25, 33, 34, and 42–46.
`
`Vol. 37 No. 6 (cid:129) June 2012 (cid:129) P&T® 347
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1016 - Page 3
`
`

`
`Management of Urinary Incontinence
`
`often overlooked, but if the disorder is identified in these individ-
`uals, it can be successfully managed with conservative measures.
`The use of nonpharmacological interventions, including Kegel
` exercises and bladder retraining, can be effective even in frail older
`adults, especially with caregiver assistance. Medications may be
`necessary in some patients, however, and treatment outcomes may
`be less successful in patients with advanced age and severe UI.73
`
`Pharmacotherapy: Estrogen Replacement
`The loss of estrogen during menopause has multiple effects on
`postmenopausal women, including atrophic tissue changes in the
`urogenital tract. These physiological changes may result in dry-
`ness, burning, itching, dyspareunia, and infections along with
` additional LUTS, including frequency and urgency.74–77 Hormone
`therapy (HT) has always been considered a therapeutic option for
`the management of postmenopausal symptoms. HT offers signif-
`icant benefits in the management non-urogenital features, such as
`hot flashes, and may relieve the vaginal dryness associated with
`menopause. In addition, HT has been used to improve LUTS be-
`cause of its effect on estrogen receptors in the urogenital area.78,79
`During the past decade, the use of exogenous estrogen in post-
`menopausal women has become controversial because of con-
`cerns about increased rates of breast cancer and the risk of vascular
`disease–related morbidity (e.g., clotting and stroke).80 The role of
`estrogen in the management of UI is also contro versial because data
`have suggested that HT provides only minimal benefit in UI and
`may even exacerbate the disorder.81–85 The basis for the assump-
`tion that estrogen would be beneficial in UI is the presence of es-
`trogen and progesterone receptors throughout the genital tract,
`bladder, and vaginal epithelium. The presence of these receptors
`led investigators to theorize that HT could be a useful treatment for
`UI, especially stress urinary incontinence (SUI).74–77,85–92
`Some clinical trials, however, have not supported the use of oral
`HT for managing UI.84,93 In a meta-analysis of 28 clinical studies of
`approximately 3,000 women with UI and in controlled trials of
` estrogen in more than 700 women with features of UUI and SUI,
`greater improvement of symptoms was reported for estrogen-
`treated patients with UUI than for the control groups; however, no
`beneficial effects were observed among patients with SUI.94
`Other controlled studies showed that the use of estrogen alone
`or in combination with progestin may contribute to or increase the
`incidence of UI, especially SUI, in postmenopausal women.95–102
`The Nurse Health Study reported an increased risk of UI associ-
`ated with the use of estrogen, with or without progestin therapy,
`in younger postmenopausal women (37–54 years of age).95
` Additional retrospective data from this study suggested an
` association between the use of oral contraceptives and UI in
` premenopausal women.96
`The Women’s Health Initiative (WHI), a randomized controlled
`trial involving more than 23,000 postmenopausal women 50 to 79
`years of age, reported that HT increased the incidence of UI at
`1 year; the highest incidence was in women with SUI. Estrogen
`alone or taken with progestin increased the risk of UI among con-
`tinent women and worsened the features of UI among symptomatic
`women after 1 year.97–100 The Heart Estrogen/Progestin Replace-
`ment Study (HERS), a randomized, placebo-controlled, double-
`blinded trial, evaluated conjugated estrogen plus progestin for
`the secondary prevention of heart disease in 1,200 women.
` Estrogen plus progestin increased the risk of UUI and SUI within
`4 months after initiation of treatment.101,102
`These trials showed that conjugated estrogen alone and in com-
`bination with progestin increased the risk of UI and exacerbated
`
`348 P&T® (cid:129) June 2012 (cid:129) Vol. 37 No. 6
`
`existing UI in postmenopausal women. HT, therefore, should not
`be used for the prevention or treatment of UI. Additional associa-
`tions between HT and cerebrovascular disease and breast cancer
`in postmenopausal women should further increase the reluctance
`to use HT in postmenopausal women with UI.103,104
`The role of topical estrogens in the management of UI is unclear;
`more study is needed to investigate these formulations in UI.78,105
`Evidence supports the use of topical or localized estrogen in treat-
`ing UUI caused by postmenopausal atrophic changes, which result
`in the loss of urethral support and in symptoms of UI.74,106 Topical
`estrogen formulations may include creams or estradiol-impreg-
`nated vaginal rings. The mechanisms of topical estrogen in this set-
`ting may include an increased blood supply and increased mucosal
`thickness, resulting in improved function of the lower urogenital
`system. Although these benefits have been reported in elderly
`women with atrophic changes and concurrent OAB, they have not
`been reported in women with SUI.107–109
`
`Classification and Treatment
`Urinary incontinence is usually classified in the format de-
`scribed in Table 3, although many patients may experience symp-
`toms that suggest a mixed disorder. An overview of the various
`types of UI is presented in Table 3.3,4,30,31,110–112 The next sections
`discuss urge UI, stress UI, overflow incontinence, and mixed UI.
`
`URGE URINARY INCONTINENCE
`Urge (urgency) urinary incontinence (UUI) is a common cause
`of incontinence in elderly people. It is characterized by urgency,
`followed by involuntary loss of urine. UUI is sometimes referred
`to as OAB. However, the terms are not inter changeable, because
`about two-thirds of patients with OAB do not have UI.1,31
`UUI occurs primarily as a result of detrusor muscle over activity,
`resulting in uninhibited or involuntary muscle contractions.26–28
`Patients with UUI describe a sudden desire to urinate that is dif-
`ficult to defer, resulting in leakage of urine. These episodes may
`occur at various times during the day or night.31,114 The primary
`causes of UUI (see Table 3) include idiopathic detrusor overac-
`tivity (resulting from UTIs) and neurogenic detrusor overactivity
`(resulting from stroke, trauma, neurological diseases, or medica-
`tions).25–28,43–46,112 The severity of age-related volumetric changes in
`the brain’s white matter may be associated with urinary urgency,
`and this process may have impli cations for future UI therapies.115,116
`
`Nonpharmacological Management
`The nonpharmacological management of UUI includes bladder
`training, behavioral treatments; pelvic floor exercises; the avoid-
`ance of caffeine; the use of pads for temporary bladder support;
`and, in some cases, surgery.117,118 Behavioral therapy in combina-
`tion with drug therapy has produced variable results. Behavioral
`interventions, including educational brochures with verbal rein-
`forcement, were beneficial in UUI patients who were dissatisfied
`with anticholinergic drug therapy.118 Behavioral training, includ-
`ing Kegel exercises and urge-suppression techniques, was found
`to be ineffective in improving outcomes in women with UUI.53,54,119
`
`Pharmacotherapy
`Anticholinergic (Antimuscarinic) Agents
`The current focus of pharmacotherapy for UUI is control of de-
`trusor muscle overactivity through the inhibition of M2 and M3
`muscarinic (acetylcholine) receptors on the bladder.120–122 Nu-
`merous drugs that act as acetylcholine antagonists (anticholiner-
`gic agents) are available for the treatment of UUI and can reduce
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1016 - Page 4
`
`

`
`Management of Urinary Incontinence
`
`symptoms of urgency and improve bladder control. Because mus-
`carinic receptors are located in other organ systems throughout
`the body, their inhibition can have a variety of physiological and
`adverse effects.
`The five most commonly used types of muscarinic receptors,
`their anatomic locations, and the adverse effects that can result
`from their inhibition are presented in Table 4. Table 5 lists the avail-
`able antimuscarinic (anticholinergic) agents used to treat UUI.
`Each of these agents is discussed on the following pages.123–126
`Antimuscarinic side effects are associated with both central
`and peripheral adverse reactions (see Table 4). Central adverse
`
` effects include delirium, confusion, and exacerbation of existing
`memory loss; these effects are especially concerning in elderly
` patients. Peripheral adverse effects include constipation, dry eye,
`and urinary retention.25,120,127,128
`Contraindications to the use of anticholinergic agents include
` uncontrolled narrow-angle glaucoma, a risk of urinary or gastric
`retention, the presence of underlying delirium or dementia, and
`a hypersensitivity to these drugs. Cautious use of anticholinergic
`drugs is recommended in patients with myasthenia gravis and with
`some gastrointestinal (GI) disorders, such as ulcerative colitis,
` intestinal atony, and gastroesophageal reflux disease.129–134
`
`Table 3 Causes, Symptoms, and Treatment of Urinary Incontinence
`
`Type of Incontinence
`Urge urinary incontinence (UUI)
`Idiopathic detrusor overactivity Urinary tract infections
`
`Common Causes
`
`Neurogenic detrusor
`overactivity
`
`(cid:129) Neurological disorders
`(cid:129) Parkinson’s disease
`(cid:129) Alzheimer’s disease
`(cid:129) Cerebrovascular accidents
`(e.g., stroke)
`(cid:129) Trauma
`(cid:129) Medications
`Stress urinary incontinence (SUI)
`Stress incontinence
`(cid:129) Pelvic surgery
`(outlet incompetence)
`(cid:129) Parity (childbirth)
`(cid:129) Constipation
`
`Mixed urinary incontinence (MUI)
`Mixed UUI and SUI
`(cid:129) Pelvic surgery
`(cid:129) Parity (childbirth)
`(cid:129) Constipation
`
`Common Symptoms
`
`Treatment Options
`
`Urgency and frequency,
`day or night
`
`(cid:129) Anticholinergic drugs
`(cid:129) Oxybutynin
`(cid:129) Tolterodine
`(cid:129) Surgery
`(cid:129) Intravesical Botox
`(cid:129) Sacral nerve stimulation
`
`Small volumes of urine
`loss with coughing or
`sneezing
`
`(cid:129) Weight loss
`(cid:129) Kegel (pelvic floor) exercises with
`or without biofeedback
`(cid:129) Sling procedures
`(cid:129) Transurethral collagen
`denaturation (Renessa
`procedure)
`(cid:129) Transurethral bulking agents
`
`Symptoms may include
`urge and stress features
`
`Treatment depends on predomi-
`nant symptoms
`
`Overflow incontinence (OFI)
`Overflow incontinence
`
`Other types of incontinence
`Post-prostatectomy
`incontinence
`
`(cid:129) Benign prostatic hyperplasia
`(BPH)
`(cid:129) Bladder outlet obstruction
`(cid:129) Fecal impaction
`(cid:129) Hypotonic/neurogenic bladder
`(cid:129) Urethral stricture disease
`
`Poor stream, incomplete
`emptying, and dribbling
`
`(cid:129) Alpha-adrenergic blockers
`(cid:129) 5-alpha-reductase inhibitors
`(cid:129) Intermittent catheterization
`(cid:129) Surgical options
`
`Disruption or denervation of pelvic
`floor muscle fibers
`
`Stress incontinence and
`dribbling
`
`(cid:129) Kegel pelvic floor exercises
`(cid:129) Male urethral sling
`(cid:129) Artificial urinary sphincter
`
`Fistula (e.g., colovesical or
`vesicovaginal)
`
`(cid:129) Postsurgical complications
`(cid:129) Crohn’s disease
`(cid:129) Diverticulitis
`(cid:129) Cancer
`(cid:129) Limited mobility
`(cid:129) Change in mental status
`Data compiled from references 1–4, 30, and 110–112.
`
`Functional incontinence
`
`Continuous, steady
`incontinence
`
`Surgical repair
`
`Symptoms vary
`
`Eliminate causes
`
`Vol. 37 No. 6 (cid:129) June 2012 (cid:129) P&T® 349
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1016 - Page 5
`
`

`
`Management of Urinary Incontinence
`
`Gopal et al. reported high discontinuation rates for anti -
`cholinergic drugs that were used to treat LUTS in women.135 The
`study authors estimated overall and drug-specific discontinuation
`rates for nine agents in approximately 30,000 women over a
`6-month period. Discontinuation rates were high for all anti -
`cholinergic drugs regardless of class. The overall dis continuation
`rate was 60%; oxybutynin (Ditropan, Janssen) and extended- release
`(ER) tolterodine (Detrol LA, Pfizer) were discontinued at rates of
`71% and 54%, respectively. Some limitations of the study included
`diagnoses based on electronic medical data and a lack of data
`about why patients stopped therapy. The results suggest a need for
`more effective and tolerable therapies for UUI, including more
` vigilant use of nonpharmacological interventions, such as fluid
`modification, pelvic floor rehabilitation, and bladder training.135
`Anticholinergics have the potential to interact with other med-
`ications that have the same side-effect profile and with other cen-
`trally acting drugs.120 The concomitant use of acetylcholinesterase
`inhibitors for dementia and anticholinergic drugs may exacerbate
`cognitive decline and should be avoided if possible.136
`As shown in Table 5, all of the anticholinergic agents used to treat
`UI, except trospium chloride (Sanctura, Allergan/Esprit/
`Indevus), are metabolized by hepatic cytochrome P450 (CYP)
` enzymes; inhibitors of these enzymes, therefore, may potentiate the
`adverse effect of anticholinergic drugs. Clinicians should monitor
`patients with UUI, especially older adults and those taking multiple
`medications, for adverse effects, drug interactions, and potential
` contraindications during treatment with anticholin ergics.25,120,137
`Older drugs, such as propantheline (Pro-Banthine, Shire),
` dicyclomine (Bentyl, Axcan Pharma), and flavoxate (Urispas,
`Ortho-McNeil), are still available, but they are rarely used because
`of their questionable efficacy and side-effect profiles. The tricyclic
` antidepressant imipramine (Tofranil, Mallinckrodt) has been used
`to treat patients with UUI and may have a role in MUI because of
`its dual anticholinergic and alpha-adrenergic properties.120, 128,138–141
`Currently, the anticholinergic drugs most commonly used in
`clinical practice for the treatment of UUI include transdermal
` oxybutynin (Oxytrol, Watson Pharma), oxybutynin gel (Gelnique,
`Watson Pharma), tolterodine (Detrol and Detrol LA, Pfizer),
` trospium chloride, darifenacin (Enablex, Novartis), solifenacin
`(VESIcare, Astellas/GlaxoSmithKline), and ER fesoterodine
`(Toviaz, Pfizer) (see Table 5).138–141
`As mentioned, several anticholinergic agents are available in var-
`ious doses, formulations, and routes of administration, providing
`clinicians with several treatment options for with UUI.128,132,137,138,141
`
`These drugs are usually used to treat UUI and OAB in patients who
`have not achieved symptom relief and improved quality of life
`with conservative nonpharmacological interventions.
`
`Clinical Efficacy
`Efficacy data for anticholinergic drugs in patients with UUI have
`been obtained from a number of meta-analyses and head-to-head
`trials. Two large meta-analyses reported similar clinical efficacy
`among the available anticholinergic agents, as measured by
` reductions in episodes of urgency and incontinence, frequency,
`daily micturition, nocturnal awakenings, increased volume per
`void, patient satisfaction, and quality of life.141,142 Another meta-
`analysis included data from 50 randomized controlled trials and
`three pooled analyses that included various formulations and doses
`of anticholinergic agents. This study reported advantages with ER
` formulations in terms of efficacy and safety. Dose escalations with
` immediate-release (IR) formulations provided some improvement
`in efficacy but with an increased risk of adverse events.143
`Head-to-head trials with anticholinergic agents have reported
`similar efficacy or insignificant differences among the various
`drugs. Tolerability differences were evident in some studies,
` especially when other drugs were compared with IR oxybutynin.
`One report described the available anticholinergic agents as equiv-
`alent first choices, except for oral oxybutynin administered at
`dosages of more than 10 mg/day, which were associated with a
`higher rate of adverse effects.144 The study data showed a smaller
`treatment effect with anticholinergics compared with placebo than
`what might be expected in clinical practice. This difference might
`have been due to the use of concurrent bladder training in some
`patients who were prescribed these drugs in the clinical setting,
`compared with the absence of this intervention in clinical trials. The
`literature is devoid of direct comparisons between anticholinergic
`drugs and bladder-training interventions.53,54,142–147
`Oxybutynin (Ditropan, Oxytrol). Oxybutynin is the oldest of
`the agents currently used to treat UUI. It is available in IR and ER
`oral formulations (Ditropan and Ditropan XL, Janssen), along
`with a dermal patch and topical gel formulations (see Table 5).
`Oxybutynin is considered the gold standard with which other
`agents in the class are compared. Trial data indicate that the effi-
`cacy of oxybutynin is similar to that of other anticholinergic drugs.
`The significance of its proposed muscle-relaxant properties is
` unclear.148 The ER tablet, dermal patch, and topical gel may offer
`improved tolerability because of reduced levels of the active
`metabolite, N-desethyloxybutynin.149–153
`
`Table 4 Muscarinic Receptor Subtypes and Adverse Effects of Receptor Inhibition
`
`Organ System
`Bladder (detrusor muscle)
`
`Receptor Subtype
`M2, M3
`
`Adverse Effects of Inhibition (Anticholinergic Effects)
`Decreased contractions; urinary retention
`
`Cardiac tissue
`
`M2
`
`Tachycardia; palpitations
`
`Central nervous system and brain
`(cortex and hippocampus)
`
`M1, M2, M3, M4, M5
`
`Effects on memory, cognition, and psychomotor speed; confusio

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket